医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Imperial College London to Present First Public HBV Data from CN Bio in Vitro Liver Model

2014年09月02日 PM10:00
このエントリーをはてなブックマークに追加


 

OXFORD, England

CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations at three international meetings this Fall, including:

• The 2014 International Meeting on Hepatitis B in Los Angeles, USA (3-6 September, 2014)

• The Viral Hepatitis Congress 2014 in Frankfurt, Germany (9-11 October, 2014)

• The Liver Meeting® 2014*, Boston USA (7-11 November, 2014). CN Bio will also host an Investigator Meeting** on Monday 10th November, which is an invitation-only event for attendees of The Liver Meeting® 2014.

First public presentations

Dr Marcus Dorner, Lead Principle Investigator for the study, commented: “It’s an honour to be invited to present our data at these prestigious meetings, where we’ll show how CN Bio’s Hepatitis B liver disease model accurately recapitulates the full life-cycle of HBV without the need for interventions such as the solvent permeabilization of cells. This makes it a uniquely powerful tool for developing and testing new HBV treatments.”

A breakthrough in HBV research

Dr Emma Sceats, COO at CN Bio said, “The work completed through this collaboration with Dr Dorner and his team represents an important breakthrough. The absence of suitable in vitro and animal models of Hepatitis B limits our ability to effectively analyse the biology and pathology of the disease, making the development of effective drugs very challenging. Hopefully, using new, advanced technologies such as these, novel therapies will reach market more quickly, helping to treat the more than 300 million patients worldwide infected with Hepatitis B.”

*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases

**This event is not an official function/event of the American Association for the Study of Liver Diseases

About CN Bio Innovations

CN Bio Innovations (CN Bio), formerly Zyoxel Ltd, is part of Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.

CONTACT

CN Bio Innovations
Ian Taylor
Commercial Director
T: +44
(0) 1865 309 600
E: ian.taylor@cn-bio.com
W:
www.cn-bio.com
or
BioStrata
Paul
Avery
Managing Director
T: +44 (0) 1223 828 200
E: pavery@biostratamarketing.com
W:
www.biostratamarketing.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease